The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial.
Twenty-two oophorectomized or postmenopausal women with metastatic breast cancer resistant to several medical therapies (tamoxifen, or other endocrine therapy, and chemotherapy) were treated in a first trial with 200 mg per day of RU486 for 1 to 3 months. The long-term tolerance was good but there was a moderate decrease in plasma potassium. Plasma cortisol was increased 2-fold without clinical hypo- or hypercorticism. Twelve patients had a partial response or a stabilization of secondary deposits for 6 weeks but the response rate at 3 months was 18%. When available, estrogen and progesterone receptor levels were positive in these patients. This preliminary trial shows for the first time that the antiprogestin RU486 is well tolerated for medium term treatment. It suggests that it might be active on advanced breast cancer becoming resistant to tamoxifen.
Romieu
G
G
Centre Paul-Lamarque, Hôpital Saint-Eloi, Montpellier, France.
Maudelonde
T
T
Ulmann
A
A
Pujol
H
H
Grenier
J
J
Cavalie
G
G
Khalaf
S
S
Rochefort
H
H
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004963:Estrenes / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000037:antagonists & inhibitors*; D006801:Humans; D015735:Mifepristone; D009362:Neoplasm Metastasis; D013997:Time Factors
D004963:Estrenes; D005938:Glucocorticoids; D015735:Mifepristone